{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.58","value":"116.90"},{"groupId":"OG001","spread":"13.51","value":"120.67"},{"groupId":"OG002","spread":"16.57","value":"123.24"},{"groupId":"OG003","spread":"18.04","value":"111.50"},{"groupId":"OG004","spread":"20.96","value":"120.00"},{"groupId":"OG005","spread":"16.66","value":"113.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.52","value":"-1.50"},{"groupId":"OG001","spread":"6.39","value":"-3.33"},{"groupId":"OG002","spread":"5.46","value":"-0.91"},{"groupId":"OG003","spread":"8.17","value":"-1.25"},{"groupId":"OG004","spread":"6.11","value":"-5.56"},{"groupId":"OG005","spread":"7.21","value":"-1.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.61","value":"-6.90"},{"groupId":"OG001","spread":"6.29","value":"-9.50"},{"groupId":"OG002","spread":"7.88","value":"-5.10"},{"groupId":"OG003","spread":"12.70","value":"-1.75"},{"groupId":"OG004","spread":"10.20","value":"-6.50"},{"groupId":"OG005","spread":"9.10","value":"-5.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.78","value":"-5.70"},{"groupId":"OG001","spread":"8.67","value":"-9.25"},{"groupId":"OG002","spread":"7.76","value":"-7.38"},{"groupId":"OG003","spread":"12.65","value":"-3.75"},{"groupId":"OG004","spread":"9.60","value":"-3.29"},{"groupId":"OG005","spread":"10.59","value":"2.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.91","value":"-6.00"},{"groupId":"OG001","spread":"9.00","value":"-8.17"},{"groupId":"OG002","spread":"8.35","value":"-5.59"},{"groupId":"OG003","spread":"14.64","value":"-0.13"},{"groupId":"OG004","spread":"8.49","value":"-2.86"},{"groupId":"OG005","spread":"12.41","value":"4.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.47","value":"-8.50"},{"groupId":"OG001","spread":"8.04","value":"-11.33"},{"groupId":"OG002","spread":"10.08","value":"-8.45"},{"groupId":"OG003","spread":"14.05","value":"0.00"},{"groupId":"OG004","spread":"13.58","value":"-5.14"},{"groupId":"OG005","spread":"13.04","value":"2.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG000","title":"RRMM Dose-evaluation: Carfilzomib 56 mg/m²"},{"description":"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG001","title":"RRMM Dose-evaluation: Carfilzomib 70 mg/m²"},{"description":"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG002","title":"RRMM Dose-expansion: Carfilzomib 70 mg/m²"},{"description":"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG003","title":"NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²"},{"description":"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG004","title":"NDMM Dose-expansion: Carfilzomib 70 mg/m²"},{"description":"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG005","title":"NDMM Dose-expansion: Carfilzomib 56 mg/m²"}],"paramType":"MEAN","populationDescription":"Participants in the safety analysis set with available data at Baseline and each time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15","title":"Change From Baseline in Hemoglobin Levels","type":"PRIMARY","unitOfMeasure":"g/L"}